Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+T cells tolerized by peptide immunotherapy

McPherson, R. C. et al. (2014) Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+T cells tolerized by peptide immunotherapy. eLife, 3, e03416. (doi: 10.7554/eLife.03416) (PMID:25546306) (PMCID:PMC4297948)

[img]
Preview
Text
109279.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Clinically effective antigen-based immunotherapy must silence antigen-experienced effector T cells (Teff) driving ongoing immune pathology. Using CD4+ autoimmune Teff cells, we demonstrate that peptide immunotherapy (PIT) is strictly dependent upon sustained T cell expression of the co-inhibitory molecule PD-1. We found high levels of 5-hydroxymethylcytosine (5hmC) at the PD-1 (Pdcd1) promoter of non-tolerant T cells. 5hmC was lost in response to PIT, with DNA hypomethylation of the promoter. We identified dynamic changes in expression of the genes encoding the Ten-Eleven-Translocation (TET) proteins that are associated with the oxidative conversion 5-methylcytosine and 5hmC, during cytosine demethylation. We describe a model whereby promoter demethylation requires the co-incident expression of permissive histone modifications at the Pdcd1 promoter together with TET availability. This combination was only seen in tolerant Teff cells following PIT, but not in Teff that transiently express PD-1. Epigenetic changes at the Pdcd1 locus therefore determine the tolerizing potential of TCR-ligation. - See more at: http://elifesciences.org/content/3/e03416#sthash.n6isQlkn.dpuf

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Prendergast, Dr Catriona
Authors: McPherson, R. C., Konkel, J. E., Prendergast, C. T., Thomson, J. P., Ottaviano, R., Leech, M. D., Kay, O., Zandee, S. E. J., Sweenie, C. H., Wraith, D. C., Meehan, R. R., Drake, A. J., and Anderton, S. M.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:eLife
Publisher:eLife Sciences Publications
ISSN:2050-084X
ISSN (Online):2050-084X
Copyright Holders:Copyright © 2014 The Authors
First Published:First published in eLife 3:e03416
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record